Cargando…

PREVALENCE OF POTENTIAL DRUG-DRUG INTERACTIONS WITH RITONAVIR-CONTAINING COVID-19 MEDICATIONS AMONG THE ADULT PATIENT POPULATION IN AUSTRALIA: ANALYSIS OF PHARMACEUTICAL BENEFITS SCHEME 10% SAMPLE (PBS10) CLAIMS

INTRO: Oral antiviral agents with differing modes of action are now available for the treatment of COVID-19. However, potentially life-threatening drug-drug interactions (DDIs) may occur if patients’ underlying co-morbidities are treated with medications that are contraindicated with ritonavir-conta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cameron, C., Chen, W.-T., Tan, W.-H., Chen, Y., Lam, C., Igho-Osagie, E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186947/ http://dx.doi.org/10.1016/j.ijid.2023.04.221

Ejemplares similares

Identifying incident cancer cases in dispensing claims: A validation study using Australia’s Repatriation Pharmaceutical Benefits Scheme (PBS) data
por: Daniels, B, et al.
Publicado: (2019)

Drug Policy Down Under: Australia's Pharmaceutical Benefits Scheme
por: Duckett, Stephen J.
Publicado: (2004)

Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy
por: Igho-Osagie, Ebuwa, et al.
Publicado: (2023)

Potential Cyp3a4-Mediated Drug-Drug Interactions with Ritonavir-Containing Medications in U.S. Patients with Diabetes or Cardiovascular Diseases: An Analysis of Nhanes Data
por: Igho-Osagie, Ebuwa, et al.
Publicado: (2022)

Number of drugs provided by the Pharmaceutical Benefits Scheme and mortality and hospital utilization in Australia, 2002–2019
por: Lichtenberg, Frank R.
Publicado: (2023)

Prevalence of Potential Drug-drug Interactions With Ritonavir-containing COVID-19 Therapy in the United States: An Analysis of the National Health and Nutrition Examination Survey
por: Igho-Osagie, Ebuwa, et al.
Publicado: (2023)

Operationalization and validation of a novel method to calculate adherence to polypharmacy with refill data from the Australian pharmaceutical benefits scheme (PBS) database
por: Arnet, Isabelle, et al.
Publicado: (2018)

The Pharmaceutical Benefits Scheme 2003–2004
por: Harvey, Ken J
Publicado: (2005)

PB2082: POPULATION-WIDE PATTERNS OF CARE IN MANTLE CELL LYMPHOMA IN AUSTRALIA: AN ANALYSIS OF THE PHARMACEUTICAL BENEFITS SCHEME DATASET
por: Tam, C., et al.
Publicado: (2022)

Relevance of the drug–drug interactions between lidocaine and the pharmacokinetic enhancers ritonavir and cobicistat
por: Dekkers, Bart G.J., et al.
Publicado: (2019)

HIV treatment regimens and adherence to national guidelines in Australia: an analysis of dispensing data from the Australian pharmaceutical benefits scheme
por: Dharan, Nila J., et al.
Publicado: (2019)

Drug-Drug Interaction Analysis of Pyronaridine/Artesunate and Ritonavir in Healthy Volunteers
por: Morris, Carrie A., et al.
Publicado: (2012)

Tacrolimus Drug–Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin
por: Sindelar, Morganne, et al.
Publicado: (2022)

Real-world use of nirmatrelvir–ritonavir: who benefits?
por: Molina, Kyle C, et al.
Publicado: (2023)

The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers
por: Mellish, Leigh, et al.
Publicado: (2015)

Interactions of the protease inhibitor, ritonavir, with common anesthesia drugs
por: Svedmyr, Anders, et al.
Publicado: (2022)

Potential drug–drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir()
por: Brandariz-Nuñez, David, et al.
Publicado: (2020)

Comment on “Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin”
por: de Oliveira, Luciana Mello, et al.
Publicado: (2023)

Benefit–cost analysis of electronic claims processing under Ghana’s National Health Insurance Scheme
por: Nonvignon, Justice, et al.
Publicado: (2022)

Australian Pharmaceutical Benefits scheme data on utilisation of intravitreal therapy in retinal vein occlusion
por: Mitchell, Paul, et al.
Publicado: (2022)

High rate of major drug–drug interactions of lopinavir–ritonavir for COVID-19 treatment
por: Macías, Juan, et al.
Publicado: (2020)

Response to Comment on “Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin”
por: Sindelar, Morganne, et al.
Publicado: (2023)

Benefits of nirmatrelvir–ritonavir remain unproven for some populations
por: McDonald, Emily G., et al.
Publicado: (2022)

Drugs and pharmaceuticals: management of intoxication and antidotes
por: Smith, Silas W.
Publicado: (2010)

Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report
por: Prikis, Marios, et al.
Publicado: (2022)

Photoluminescence Investigation of Carrier Localization in Colloidal PbS and PbS/MnS Quantum Dots
por: Zaini, Muhammad Safwan, et al.
Publicado: (2020)

Data for drugs available through low-cost prescription drug programs are available through pharmacy benefit manager and claims data
por: Zhu, Vivienne J, et al.
Publicado: (2012)

Microwave-assisted synthesis of PbS nanostructures
por: Onwudiwe, Damian C.
Publicado: (2019)

Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications
por: Agarwal, Shubham, et al.
Publicado: (2020)

Clinically relevant enantiomer specific R‐ and S‐praziquantel pharmacokinetic drug‐drug interactions with efavirenz and ritonavir
por: Mutiti, Chenai Sheilla, et al.
Publicado: (2021)

Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
por: Montanha, Maiara Camotti, et al.
Publicado: (2021)

Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series
por: Vazquez, Sara R., et al.
Publicado: (2022)

Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir
por: Gonzalez-García, Ruben, et al.
Publicado: (2023)

Comparison of claims from high–drug cost beneficiaries in Ontario, Canada, and Australia: a cross-sectional analysis
por: Tadrous, Mina, et al.
Publicado: (2021)

Liquisolid pellets: A pharmaceutical technology strategy to improve the dissolution rate of ritonavir
por: De Espíndola, Brenda, et al.
Publicado: (2019)

Comparative study of Arabidopsis PBS1 and a wheat PBS1 homolog helps understand the mechanism of PBS1 functioning in innate immunity
por: Sun, Jianhang, et al.
Publicado: (2017)

Mapping Drug Prescription, Polypharmacy, and Pharmaceutical Spending in Older Adults in Iran: A Multilevel Analysis Based on Claims Data
por: Kamyari, Naser, et al.
Publicado: (2021)

Top 10 drugs 2018–19
Publicado: (2019)

Top 10 drugs 2019–20
Publicado: (2020)

Top 10 drugs 2020–21
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gmtb69789ged8rk94s9c568cmq